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Veins  are  thin-walled  blood  vessels  suited  to 
low  shear  stress  and  high  capacitance  blood 
flow and are both structurally and molecularly 
distinct from arteries. Venous specification in 
the embryo was recently demonstrated to be 
regulated by COUP-TFII repression of Notch 
signaling, with subsequent failure to induce ex-
pression of the arterial determinant Ephrin-B2 
and allowance of expression of Eph-B4 (You   
et al., 2005). Eph-B4, a member of the Eph re-
ceptor tyrosine kinase (RTK) family, has been 
described as a marker of venous endothelial 
cell (EC) determination in embryonic develop-
ment of diverse species including mouse, chick, 
zebrafish,  and  Xenopus  laevis  (Adams  et  al., 
1999). Although Eph-B4 is an active determi-
nant of embryonic venous development (Wang 
et al., 1998; Adams et al., 1999; Gerety et al., 
1999; Shin et al., 2001), and Eph-B4 is present 
in adult veins, giving the vein a marker of 
identity, the function of Eph-B4 in adult veins 
is  currently  unknown.  Eph-B4  function  in 
adult cells has been previously associated with 
pathological functions such as angiogenesis and 
tumorogenesis (Erber et al., 2006; Foo et al., 
2006; Foubert et al., 2007). As such, it is unclear 
whether  there  is  basal  Eph-B4  function  in 
normal adult veins.
Cardiovascular disease remains the leading 
cause  of  death  worldwide.  Mortality  and 
morbidity are most frequently a result of ath-
erosclerosis in which focal arterial stenoses and 
occlusions manifest as both acute and chronic 
ischemia. Veins are frequently used for surgical 
therapy to bypass focal arterial lesions, both in 
the heart and the periphery. In particular, veins 
are the most commonly placed conduit in pe-
ripheral vascular surgery and are the gold stan-
dard for long-term clinical performance (Veith 
et al., 1986). Similarly, despite the common use 
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Eph-B4 determines mammalian venous differentiation in the embryo but is thought to be a 
quiescent marker of adult veins. We have previously shown that surgical transposition of a 
vein into the arterial environment is characterized by loss of venous identity, as indicated by 
the loss of Eph-B4, and intimal thickening. We used a mouse model of vein graft implanta-
tion to test the hypothesis that Eph-B4 is a critical determinant of venous wall thickness 
during postsurgical adaptation to the arterial environment. We show that stimulation of 
Eph-B4 signaling, either via ligand stimulation or expression of a constitutively active Eph-B4, 
inhibits venous wall thickening and preserves venous identity; conversely, reduction of  
Eph-B4 signaling is associated with increased venous wall thickness. Stimulated Eph-B4 
associates with caveolin-1 (Cav-1); loss of Cav-1 or Eph-B4 kinase function abolishes 
inhibition of vein graft thickening. These results show that Eph-B4 is active in adult veins 
and regulates venous remodeling. Eph-B4–Cav-1–mediated vessel remodeling may be a 
venous-specific adaptive mechanism. Controlled stimulation of embryonic signaling pathways 
such as Eph-B4 may be a novel strategy to manipulate venous wall remodeling in adults.
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graft failure that focus on inhibi-
tion of smooth muscle cell prolifera-
tion are not likely to be clinically 
useful (Alexander et al., 2005; Conte 
et al., 2006).
To examine the function of veins 
successfully  transplanted  into  the   
arterial environment, we previously 
determined the response of the jugular vein transposed into 
the rat carotid artery. This model showed that decreased ex-
pression  of  Eph-B4  is  associated  with  intimal  thickening 
(Kudo et al., 2007). These results suggest that Eph-B4 actively 
maintains adult venous identity by responding to the ambient 
environment, limiting venous wall thickness. A corollary to 
this proposition is the hypothesis that surgical transposition of 
a vein to the arterial environment results in loss of Eph-B4 
and venous identity and, with this loss of negative inhibition, 
subsequent alteration of venous structure and function. To 
test this hypothesis, we developed a surgical model of vein 
graft adaptation in mice and examined the effects and mecha-
nisms of altered Eph-B4 signaling on vein graft thickening 
and identity.
RESULTS
Reduced Eph-B4 during mouse and human vein  
graft adaptation
To establish a model of vein graft adaptation, we determined 
the time course of morphological and physiological changes 
in veins implanted into allogeneic C57BL/6 mice. The supra-
hepatic inferior vena cava was transplanted from a donor mouse 
into the infrarenal aorta of a recipient mouse. Laminar flow 
artery bypass, vein grafts continue to demonstrate superior 
long-term outcomes and function compared with radial ar-
tery grafts (Desai et al., 2004; Khot et al., 2004). Nevertheless, 
the response of veins transposed to the arterial environment 
remains poorly characterized (Kudo et al., 2007).
Venous adaptation to the arterial environment is charac-
terized by thickening of the venous intima, media, and adven-
titia, resulting from deposition of smooth muscle cells and 
extracellular matrix components, stimulating remodeling and 
reduced compliance by mechanisms that are thought to be 
similar to those active after arterial injury and that result in 
neointimal hyperplasia (Owens et al., 2006, 2008; Kudo et al., 
2007). In particular, Owens et al. (2006, 2008) recently dem-
onstrated positive remodeling, e.g., increased diameter and 
wall thickness, in clinically successful human vein grafts with 
high resolution imaging. However, it is not currently under-
stood which aspects of remodeling are critical for successful 
vein graft function in an arterial environment. It is also not 
known to what extent wall thickening is adaptive and at 
what point the remodeling and thickening becomes patho-
logical or even how excessive thickening might contribute to 
vein graft failure. The disappointing failure of the PREVENT-III 
and PREVENT-IV trials show that strategies to prevent vein 
Figure 1.  Venous expression of Eph-B4 
during vein graft adaptation in both a 
mouse model and in human specimens. 
(A–C) Expression of ephb4 (A), efnb2 (B), 
and opn mRNA (C). n = 4. IVC, inferior  
vena cava; VG, vein graft; Ao, aorta. Error 
bars denote SEM. (D) Eph-B4 and Ephrin-B2 
immunoreactivity at 3 wk of vein graft ad-
aptation in mice. Photomicrographs show 
representative samples from n = 4 indepen-
dent samples for each group. Bars, 100 µm. 
Black arrows show the vein graft wall. Red 
arrowheads indicate Eph-B4– and Ephrin-
B2–positive signals. (E) Eph-B4 immunore-
activity during human vein graft adaptation. 
Representative photomicrographs from two 
independent samples are shown. Bar, 250 µm. 
Red arrowheads point to the Eph-B4– 
positive signal. (F) Distribution of Eph-B4  
in mouse veins (n = 4) as determined by 
immunofluorescence. The density of cells 
immunoreactive for both Eph-B4 and either 
CD31 or -actin was analyzed by ImageJ 
(National Institutes of Health). **, P < 0.01;  
*, P < 0.05. Error bars denote SEM.JEM VOL. 208, March 14, 2011 
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gene expression, a marker of vein graft adaptation (Abeles   
et al., 2006; Fig. 1 C). Similarly, there was diminished Eph-B4 
protein in all layers of mouse vein grafts compared with strong 
detection  in  veins,  and  there  was  no  increased  detectable 
Ephrin-B2 protein in the mouse vein grafts wall (Fig. 1 D). 
Diminished Eph-B4 protein in vein grafts was a pattern also 
found in patent human vein grafts (Fig. 1 E). To identify the 
distribution of Eph-B4 immunoreactivity within the native 
vein wall, we analyzed the relative distribution of Eph-B4 in 
ECs and smooth muscle cells of both abdominal and thoracic 
mouse inferior vena cava (Fig. 1 F). Eph-B4 was distributed 
predominantly on ECs, with ECs showing three times more 
immunoreactivity compared with smooth muscle cells, with a 
similar ratio in the thoracic and abdominal vena cavae (un-
published data).
Eph-B4 is active and limits wall thickness in adult veins
Diminished Eph-B4 expression without induction of Ephrin-B2 
expression is consistent with our hypothesis that Eph-B4 
actively limits venous wall thickness in adult veins, and   
was preserved by suturing the anastomoses in standard micro-
surgical fashion and confirmed by ultrasonography. Vein 
graft wall thickness increased in a time-dependent manner, 
with increased wall thickness up to 6 wk after implantation 
(Fig. S1). Serial observations of vein grafts using ultrasound 
imaging showed that increased vein graft wall thickness and 
reduced compliance reach a plateau at 4–6 wk, with only a 
small amount of positive remodeling until 8 wk (Fig. S1 F). 
Surprisingly, vein grafts showed some late positive remodeling 
by 12 wk, consistent with results of late dilation and aneurysmal 
degeneration in long-standing functional human vein grafts 
(Szilagyi et al., 1973; Loftus et al., 1999). Therefore, the mouse 
vein graft model closely mimics early human vein graft adap-
tation, at least until 3–4 wk (Owens et al., 2006, 2008).
We have previously demonstrated decreased Eph-B4 gene 
expression, without increased Ephrin-B2 gene expression, in 
a rat model of vein graft adaptation (Kudo et al., 2007). Mouse 
vein grafts also showed decreased Eph-B4 gene expression 
and no change in Ephrin-B2 expression (Fig. 1, A and B).   
As expected, mouse vein grafts showed increased osteopontin 
Figure 2.  Recombinant Ephrin-B2/human IgG Fc chimeric protein activates the Eph-B4 receptor in vitro. (A) EC expression of Eph-B4 (green), 
phosphotyrosine (red), or both (merge) after 5 min of treatment with 2 µg/ml of control CD6/Fc or 2 µg/ml Ephrin-B2/Fc. Bar, 50 µm. (B) Immunoprecipi-
tation analysis of tyrosine-phosphorylated Eph-B4 (arrowhead) in EC treated with Ephrin-B2/Fc. *, IgG heavy chain; **, IgG light chain. Bottom shows 
total cell lysate. (C) Expression of VCAM and ICAM on EC treated with Ephrin-B2/Fc. n = 3. (D) Migration of WT EC in response to Ephrin-B2/Fc, control 
CD6/Fc, or VEGF. n = 3. Error bars denote SEM. (E) Migration of WT or Eph-B4+/ EC in response to Ephrin-B2/Fc or FBS. n = 3. **, P < 0.01; *, P < 0.05. 
Error bars denote SEM.564 Eph-B4 prevents venous remodeling | Muto et al.
manner in WT EC (Fig. 2 D) with reduced migration in Eph-
B4+/–derived EC (Fig. 2 E). Stimulation of migration in WT 
venous EC is consistent with the EC being Eph-B4 positive and 
Ephrin-B2 negative, as previously reported (Steinle et al., 2002).
We hypothesized that stimulation of Eph-B4 signaling in 
veins transplanted to the arterial environment would promote 
retention of Eph-B4, preventing venous intimal thickening 
with maintenance of venous thin-wall architecture. To stimu-
late Eph-B4 in surgically implanted vein grafts, Ephrin-B2/Fc 
was injected intraperitoneally from the day before surgical 
implantation and then every other day after surgical vein graft 
diminished Eph-B4 expression during vein graft adaptation 
allows increased wall thickness. To confirm this hypothesis, 
we examined vein grafts with both increased and reduced 
Eph-B4 signaling. To determine the response of veins implanted 
into the arterial environment, but with increased Eph-B4 sig-
naling, Eph-B4 signaling was first stimulated with its soluble li-
gand Ephrin-B2/Fc. Consistent with previous studies and as 
expected, Ephrin-B2/Fc induces Eph-B4 phosphorylation in 
venous ECs in vitro (Fig. 2, A and B), without induction of a 
dysfunctional endothelial phenotype (Fig. 2 C). In addition, 
Ephrin-B2/Fc also stimulates migration in a dose-dependent 
Figure 3.  Ephrin-B2/Fc activates Eph-B4 and decreases vein graft wall thickness in vivo. (A) Immunofluorescence of anti–human IgG-FITC in whole 
mount inferior vena cava (IVC) isolated from mice 24 h after injection with control CD6/Fc or Ephrin-B2/Fc. Representative photomicrographs from three 
independent samples are shown. Bar, 20 µm. (B) Expression of Eph-B4 (green), phosphotyrosine (red), or both (merge) in pulmonary vein (PV), inferior vena 
cava, or vein graft (VG) of mice after 3 wk of treatment with control CD6/Fc or Ephrin-B2/Fc. Representative photomicrographs from three independent sam-
ples are shown. Star indicates vessel lumen. Arrows show vein graft wall. Bars, 20 µm. pTyr, phosphotyrosine. (C) Mouse body weight during treatment with 
control CD6/Fc or Ephrin-B2/Fc. Error bars denote SEM. (D, G, and H) Mouse vein grafts after 3 wk of treatment with control CD6/Fc or Ephrin-B2/Fc, exam-
ined with H&E staining (D), immunoreactivity against -actin (SMA; G), or immunofluorescence against Eph-B4 (H). Arrowheads show vein graft wall.  
*, lumen. Bars, 20 µm. (E and F) Vein graft wall thickness and lumen/total vessel area after control CD6/Fc or Ephrin-B2/Fc treatment. Error bars denote SEM.  
(I and J) Percentage of cells in the walls of the inferior vena cava or vein grafts, treated with control CD6/Fc or Ephrin-B2/Fc and positively staining for prolif-
eration (I) or apoptosis (J). Error bars denote SEM. All experiments analyzed five (CD6/Fc) and seven (Ephrin-B2/Fc) mice. *, P < 0.05; **, P < 0.01.JEM VOL. 208, March 14, 2011 
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with retention of venous identity. In addition, vein 
grafts derived from Ephrin-B2/Fc–injected mice 
showed increased colocalization of Eph-B4 and 
phosphotyrosine in the endothelium (Fig. 3 B, bot-
tom), which is consistent both with Ephrin-B2/Fc 
stimulation  of  Eph-B4  and  retention  of  Eph-B4   
in the endothelium (Fig. 3 H). These vein grafts   
also  showed  diminished  proliferation  and  in-
creased apoptosis compared with control vein grafts 
(Fig. 3, I and J).
It is possible that the Fc moiety of Ephrin-B2/Fc 
could activate complement or macrophages, pro-
viding an alternative mechanism to regulate vein 
graft wall thickness (Stabila et al., 1998; Tawara   
et al., 2008). However, there were no differences 
in complement activation or numbers of infiltrating 
macrophages in vein grafts derived from control 
or Ephrin-B2/Fc–injected mice (Fig. S2), suggesting 
that the thinner vein grafts in Ephrin-B2/Fc–injected 
mice (Fig. 3, D, E, and G) are mediated by altered 
Eph-B4 signaling rather than by stimulation of   
either complement or macrophages.
To show that the remodeling response is intrin-
sic to the vein graft, and to confirm the hypothesis that re-
duced Eph-B4 signaling results in thicker vein grafts, we used 
a genetically modified mouse with reduced Eph-B4 signaling 
as previously described (Gerety et al., 1999). Homozygous 
deletion of Eph-B4 is an embryonic lethal phenotype. Het-
erozygous KO mice (Eph-B4+/) were used as a source of 
veins with diminished Eph-B4 signaling. Compared with   
WT veins, veins derived from Eph-B4+/ mice have similar 
morphology and thickness before implantation as vein grafts 
(Fig. 4 A). Eph-B4+/ veins implanted into littermate host 
mice were 100% thicker than WT veins, with approximately 
twice as many layers of -actin–positive cells (Fig. 4, B and C). 
To confirm that the thickening response was associated with 
the vein graft, veins derived from littermate or Eph-B4+/ 
mice were implanted into Eph-B4+/ host mice. These veins 
showed similar patterns of thickening to those in veins im-
planted into WT hosts (Fig. 4, B and C), confirming that   
diminished Eph-B4 signaling in the vein graft promotes   
vein graft thickening. Despite increased wall thickness in vein 
grafts derived from Eph-B4+/ mice, lumen encroachment 
and outward vessel remodeling did not achieve significance 
implantation until vein graft harvest, as previously described 
(Noren et al., 2006). 24 h after intraperitoneal injection, 
Ephrin-B2/Fc, but not control CD6/Fc, was detectable in 
veins, confirming its in vivo localization to Eph-B4–positive 
tissue (Fig. 3 A, right, green) and, therefore, its suitability to stimu-
late Eph-B4 signaling in vein grafts. 3 wk after injection, there 
was increased colocalization of Eph-B4 and phosphotyrosine 
in pulmonary EC as well as EC lining the inferior vena cava, 
suggesting increased Eph-B4 pathway phosphorylation after 
administration of Ephrin-B2/Fc in vivo (Fig. 3 B, top and 
middle). Despite 3 wk of Ephrin-B2/Fc treatment, mice did 
not suffer any adverse clinical events; mean body weight was 
unchanged compared with control mice (Fig. 3 C). Notably, 
after Ephrin-B2/Fc treatment, vein grafts showed reduced 
wall thickness and reduced numbers of layers of -actin–positive 
cells compared with control (CD6/Fc injected) vein grafts 
(Fig. 3, D, E, and G). Although control vein grafts showed di-
minished Eph-B4 expression and loss of venous identity in 
the arterial environment, as previously shown (Fig. 1, A and D), 
vein grafts derived from Ephrin-B2/Fc–injected mice showed 
retention of Eph-B4 expression (Fig. 3 H), which is consistent 
Figure 4.  Increased intimal thickening in vein grafts 
derived from Eph-B4+/ mice (4 wk). (A) Histology of veins 
derived from WT (WT) or Eph-B4 heterozygous KO (Eph-B4+/) 
mice stained with H&E. Bar, 50 µm. (B) Morphology of vein 
graft adaptation of WT or Eph-B4+/ vein grafts placed into 
WT or Eph-B4+/ hosts, examined with H&E staining or 
smooth muscle -actin (SMA) immunoreactivity. Arrows show 
intimal thickening. Bar, 100 µm. (C–E) Vein and vein graft wall 
thickness (C), vein graft lumen area (D), and total vein graft 
area (E). Error bars denote SEM. (F) Numbers of CD3 immuno-
reactive cells infiltrated into veins and vein grafts. Error bars 
denote SEM. n = 5–7 in each group. **, P < 0.01.566 Eph-B4 prevents venous remodeling | Muto et al.
These residues in the kinase domain have been reported to   
be an important for the catalytic role of RTK (García-Cardeña 
et al., 1997; Nystrom et al., 1999; Abulrob et al., 2004; Vihanto   
et al., 2006). Transfection of WT Eph-B4 plasmid DNA into 
HEK293  cells  showed  time-dependent  Eph-B4  tyrosine 
phosphorylation in response to Ephrin-B2/Fc (Fig. 5 A) as 
well  as  time-dependent  association  with  the  downstream   
effector RasGAP (Fig. 5 B). Transfection of cells with either 
WT or mutant plasmids expressing a single amino acid   
substitution in Eph-B4 (w804a or w811f; Vihanto et al., 
2006) resulted in expression of Eph-B4 at the cell membrane 
(Fig. 5 C) and intracellular vesicles (Fig. 5 E, arrowheads). Al-
though both WT and mutant Eph-B4 were expressed at the 
cell membrane, only WT Eph-B4 colocalized with Cav-1   
after treatment with Ephrin-B2/Fc (Fig. 5, C and E). HEK293 
(Fig. 4, D and E). There were no significant differences in 
CD3+ infiltrating cells in any of the vein grafts, demonstrating 
that the thickened Eph-B4+/–derived vein grafts were not a 
result of T cell–mediated responses (Fig. 4 F). These results are 
consistent with our hypothesis that Eph-B4 is active in adult 
veins and plays a role in limiting vein graft wall thickness 
during vein graft adaptation.
Eph-B4 phosphorylation is a critical determinant of venous 
adaptation to the arterial environment
To test the importance of Eph-B4 function during vein graft 
adaptation, we mutated a single site in the kinase domain of 
the Eph-B4 receptor, which has the conserved consensus se-
quence WSYGIVMW at residues 804–811 in mice, either from 
tryptophan to alanine (site 804) or to phenylalanine (site 811). 
Figure 5.  Plasmids with mutated Eph-B4 kinase domain have defective Eph-B4 phosphorylation. (A) Time course of Eph-B4 phosphorylation, 
stimulated with 2 µg/ml Ephrin-B2/Fc, in HEK293 cells transfected with HA-tagged mEph-B4 plasmid. (B) Time course of Ras-GAP association with Eph-B4, 
stimulated with 2 µg/ml Ephrin-B2/Fc, in HEK293 cells transfected with HA-tagged mEph-B4 plasmid. (C) Immunofluorescence for HA-tagged Eph-B4  
in HEK293 cells transfected with either mEph-B4 wt plasmid or mutant (w804a and w811f) mEphB4 plasmids, counterstained with DAPI. Bar, 50 µm.  
(D) Tyrosine phosphorylation in response to Ephrin-B2/Fc in HEK293 cells transfected with WT or mutant (w804a and w811f) mEph-B4 plasmids. (E) Immuno-
fluorescence of HA-tagged Eph-B4 (green), cav-1 (red), or merge (yellow) in COS cells transfected with WT or mutant Eph-B4 plasmids, counterstained 
with DAPI, and without or with stimulation with Ephrin-B2/Fc. White arrowheads show Eph-B4 in the intracellular vesicles. Red arrowheads show  
colocalization of Eph-B4 with cav-1 at the cell membrane, after treatment with Ephrin-B2/Fc, in WT but not mutant Eph-B4 plasmids. Bar, 100 µm.  
(F) Tyrosine phosphorylation in response to Ephrin-B2/Fc in COS cells transfected with WT or mutant (w804a, w811f) mEph-B4 plasmids. (G) Ras-GAP or 
Ephexin association with Eph-B4, stimulated with 2 µg/ml Ephrin-B2/Fc, in COS cells transfected with HA-tagged mEph-B4 plasmid. All panels show rep-
resentative samples from three independent experiments. WCL, whole cell lysate.JEM VOL. 208, March 14, 2011 
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Vein grafts transfected with WT Eph-B4–expressing adenovi-
rus (Ad-Eph-B4 wt), e.g., with functional Eph-B4 signaling, 
showed significantly reduced wall thickness (Fig. 6, F, G [middle], 
and H), which is similar to the thin vein graft wall seen with 
Ephrin-B2/Fc treatment (Fig. 3, D and E). These results con-
firm that stimulation of Eph-B4 signaling prevents wall thick-
ening during vein graft adaptation. Adventitial macrophages 
may represent a reservoir of adenovirus mediating Eph-B4 
function. Vein grafts transfected with the adenovirus coding 
for mutant Eph-B4 (Ad-Eph-B4 w804a), e.g., without func-
tional Eph-B4 signaling, showed similar wall thickness as con-
trol vein grafts (Fig. 6, F, G [right], and H), confirming our 
results which show that Eph-B4 signaling and function medi-
ate vein graft adaptation (Fig. S5).
Eph-B4 signaling is linked with caveolin-1 (Cav-1)
To determine a mechanism by which Eph-B4 limits vein 
graft wall thickness during vein graft adaption, we examined 
Cav-1 function during vein graft adaptation. Cav-1 is a major 
structural protein of caveolae in EC and is thought to be in-
volved  with  mechanotransduction  of  dynamic  shear  stress 
changes by interaction with several signaling protein families, 
including G protein–coupled receptors, eNOS, 1-integrin, 
Src, Jak-Stat, ERK 1/2, and several RTKs including Eph re-
ceptors (Gratton et al., 2004;  Yu et al., 2006). We hypothesized 
that Cav-1 and Eph-B4 interact during vein graft adaptation 
because Cav-1 interacts with several RTKs (Couet et al., 
1997b; Yamamoto et al., 1998; Nystrom et al., 1999; Lajoie   
et al., 2007) and, in particular, Cav-1 has been shown to   
be  required  for  Eph-B1  receptor  downstream  signaling   
or COS cells transfected with mutant Eph-B4 showed inabil-
ity to phosphorylate tyrosine in response to Ephrin-B2/Fc, 
compared with stimulated tyrosine phosphorylation in cells 
transfected with WT Eph-B4 (Fig. 5, D and F). Mutant Eph-
B4 still retained the ability to bind to downstream effectors 
RasGAP and Ephexin, similar to WT Eph-B4 (Fig. 5 G), sug-
gesting that the defects in tyrosine phosphorylation in the 
mutant Eph-B4 are specific. These results suggest that WT 
Eph-B4 stimulates Eph-B4 phosphorylation and cav-1 colo-
calization and that mutations of the kinase domain of Eph-B4 
fail to phosphorylate tyrosine.
To test this idea during vein graft adaptation, adenoviral 
vectors were generated from plasmids encoding WT Eph-B4 
and the Eph-B4 point mutation w804a. Adenovirus with WT 
Eph-B4 retained the ability to induce tyrosine phosphoryla-
tion in EC in vitro, whereas adenovirus with mutant Eph-B4 
w804a did not (Fig. 6 A), which is similar to the activities of 
the original plasmid (Fig. 5, D and F). Vein grafts were trans-
fected with 1.0 × 109 pfu adenovirus, first applied ex vivo for 
20 min before implantation and then with additional treat-
ment to the adventitia in vivo using pluronic gel containing 
the remainder of the adenovirus (Mann et al., 1999; Alexander   
et al., 2005; Conte et al., 2006). Adenovirus was present in 
both the endothelium and the adventitia of both control and 
Eph-B4–transfected vein grafts (Fig. 6 B). Adenovirus was re-
tained both in endothelium and adventitial macrophages, but 
not medial smooth muscle cells, in transfected vein grafts 
(Fig. 6, C–E). Vein grafts transfected with control adenovirus 
(Ad-GFP) developed wall thickening (Fig. 6, F and G [left]), 
which was similar to that previously demonstrated (Fig. S1). 
Figure 6.  Eph-B4 inhibition of vein graft 
thickening depends on a functional Eph-B4 
kinase domain. (A) Tyrosine phosphorylation 
on Eph-B4 in EC transfected with Ad-Eph-B4 
wt or Ad-Eph-B4 w804a. n = 3. (B and G) Vein 
grafts, transfected with Ad-GFP, Ad-Eph-B4 
wt, or Ad-Eph-B4 w804a, were implanted into 
WT mice for 3 wk and then examined for GFP 
immunofluorescence (B) or H&E staining (G). 
Arrows show vein graft wall. Bars, 50 µm.  
(C–E) Immunofluorescence of CD31 (red) and 
GFP (green; C), SM -actin (red) and GFP 
(green; D), and F4/80 (red) and GFP (green; E) 
in Ad-Eph-B4 wt-transfected vein grafts. Bars, 
20 µm. Arrowheads show colocalized cells.  
*, lumen. (F) Vein graft wall thickness as deter-
mined by serial ultrasounds in mice. Vein 
grafts were control grafts (filled circle) or 
treated with Ad-Eph-B4 wt (filled red square) 
or Ad-Eph-B4 w804a (empty red square). Error 
bars denote SEM. (H and I) Vein graft wall 
thickness, and lumen and total vessel area, 
after 3 wk, in vein grafts transfected with  
Ad-GFP, Ad-Eph-B4 wt, or Ad-Eph-B4 w804a. 
**, P < 0.01. n.s., not significant. Error bars 
denote SEM. B-I show representative data 
from n = 6 independent samples.568 Eph-B4 prevents venous remodeling | Muto et al.
(red fluorescence) under basal conditions but colocaliza-
tion of Eph-B4 with Cav-1 after activation of Eph-B4 with 
Ephrin-B2/Fc (Fig. 7 C). Similarly, the interaction of Eph-B4 
and Cav-1, detected with immunoprecipitation, is enhanced 
after activation of Eph-B4 with Ephrin-B2/Fc (Fig. 7 D). 
EC derived from Cav-1 KO mice showed a 50% reduction of 
Ephrin-B2/Fc–induced migration, compared with WT EC, 
which was rescued by Cav-1 reconstitution (Fig. 7 E). Similarly, 
EC derived from Cav-1 KO mice showed loss of Ephrin-B2/
Fc–induced nitric oxide production, compared with WT EC, 
which was rescued by Cav-1 reconstitution (Fig. 7 F). These 
results suggest that Eph-B4 signaling is regulated by Cav-1.
To determine if Eph-B4 signaling stimulates Cav-1 phos-
phorylation, we examined the effects of Ephrin-B2/Fc on 
EC both in vitro and in vivo. WT venous EC and venous EC 
derived from Eph-B4+/ mice were examined by FACS and 
Western blotting. As expected, EC derived from Eph-B4+/ 
mice showed 50% fewer Eph-B4 surface receptors (Fig. 8 A), 
as well as the presence of Myc reactivity, which is indicative 
of the targeted Eph-B4 deletion (Fig. 8 B). Stimulation of 
Eph-B4 signaling in vitro resulted in increased phosphoryla-
tion of Cav-1 on tyrosine-14 (Y14) in WT EC, compared 
with control EC. This tyrosine phosphorylation of Cav-1 was 
(Vihanto et al., 2006). In addition, Eph-B4 is predominantly 
distributed in the venous endothelium (Fig. 1 F), which is in 
physical proximity to Cav-1. Our experimental results show-
ing increased intimal thickening in vein grafts derived from 
Eph-B4+/ mice compared with WT mice, despite morpho-
logically similar preimplantation veins (Fig. 5), are consistent 
with effects of impaired endothelial mechanotransduction in 
response to transposition to the arterial environment, further 
suggesting the possibility that Eph-B4 activity may be regu-
lated by Cav-1 (Couet et al., 1997a; Rizzo et al., 1998; Murata 
et al., 2007).
Eph-B4 is present in EC derived from WT mice, Cav-1 
KO mice, and Cav-1 KO mice with EC-specific reconstitu-
tion of Cav-1 (Cav-1 RC; Fig. 7 A; Yu et al., 2006; Murata   
et al., 2007). Sucrose gradient analysis showed cosedimentation 
of Eph-B4 within the light membrane-enriched fractions in 
both WT and Cav-1 KO EC (Fig. 7 B). Cosedimentation of 
Eph-B4 within the light membrane–enriched fractions was 
not an artifact of EC isolation and culture because Eph-B4 
cosedimented with the light membrane–enriched fractions of 
the original lung tissue in both WT and Cav-1 KO mice 
(Fig. S3). In WT EC, immunofluorescence showed distinct 
localization  of  Eph-B4  (green  fluorescence)  and  Cav-1 
Figure 7.  Eph-B4 signaling is linked to Cav-1 in vitro. (A) Eph-B4 expression in ECs derived from WT mice, Cav-1 KO mice, or Cav-1 KO mice with 
EC-specific reconstitution of Cav-1 (Cav-1 RC). n = 3. Bar, 50 µm. (B) Sucrose gradient analysis of WT EC or Cav-1 KO EC. n = 3. (C) Immunofluorescence 
of Eph-B4 (green), cav-1 (red), or both (merge) in EC stimulated with control CD6/Fc or Ephrin-B2/Fc. Arrowheads show colocalization. n = 3. (D) Cav-1 
association with Eph-B4, stimulated with 2 µg/ml Ephrin-B2/Fc, in EC. n = 3. (E) Migration of WT, Cav-1 KO, or Cav-1 RC EC in response to CD6/Fc, Ephrin-
B2/Fc, or FBS. n = 3. *, P < 0.05; **, P < 0.01. Error bars denote SEM. (F) Nitric oxide production by WT, Cav-1 KO, or Cav-1 RC EC in response to control or 
Ephrin-B2/Fc. n = 3. *, P < 0.05. Error bars denote SEM. NCT, negative control. n.s., not significant.JEM VOL. 208, March 14, 2011 
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third row), phosphorylated Cav-1 was reduced in vein grafts 
compared with preimplantation veins (Fig. 8 E, second and 
bottom rows). In addition, phosphorylated Cav-1 was re-
duced in the endothelium of vein grafts derived from Eph-
B4+/ mice compared with WT mice (Fig. 8 F) and increased 
in the endothelium of WT vein grafts treated with Ephrin-
B2/Fc compared with control vein grafts (Fig. 8 G). These 
results suggest that Eph-B4 stimulates phosphorylation of Cav-1 
in EC, both in vitro and in vein grafts in vivo. In addition, 
reduced in EC derived from Eph-B4+/ mice (Fig. 8, B and C). 
These results are consistent with disturbance of both Eph-B4 
and Cav-1 signaling in EC derived from Eph-B4+/ mice.
Eph-B4 stimulation of Cav-1 phosphorylation was also 
tested in vivo. As expected, Cav-1 phosphorylation was not 
detected in veins derived from Cav-1 KO mice (Fig. 8 D). 
Cav-1 was expressed in WT preimplantation veins as well as 
in vein grafts (3 wk) in vivo (Fig. 8 E, top row). However, 
similar to the reduction in Eph-B4 in vein grafts (Fig. 8 E, 
Figure 8.  Eph-B4 activation stimulates Cav-1 phosphorylation in vitro and in vivo. (A) FACS analysis of venous EC derived from WT or Eph-B4+/ 
mice. Ephrin-B2/Fc was allowed to bind to EC and then detected with anti–Fc-FITC. Control groups did not include the anti–Fc-FITC antibody. n = 3.  
(B) Phosphorylation of Cav-1 on tyrosine-14 (Y14) in WT or Eph-B4+/ EC stimulated with control CD6/Fc or Ephrin-B2/Fc. n = 3. (C) WT or Eph-B4+/ EC 
expression of phosphorylated-Cav-1 (red), stimulated with control CD6/Fc or Ephrin-B2/Fc. n = 3. Bar, 50 µm. (D) Expression in inferior vena cava (IVC) of 
Cav-1 WT or Cav-1 KO mice of phosphorylated Cav-1 (red). n = 3. Bar, 50 µm. (E) Expression in inferior vena cava, vein graft (VG), or aorta (Ao) of WT 
mice, of Cav-1 (green, top two rows), Eph-B4 (green, bottom three rows), phosphorylated Cav-1 (red), and both (merge). Bar, 50 µm. n = 3. Arrowheads 
denote loss of pCav-1 signal. (F) Expression in vein grafts derived from WT or Eph-B4+/ mice of CD31 (green), phosphorylated Cav-1 (red), or both 
(merge). Counterstain is with DAPI (blue). Bar, 20 µm. n = 3. (G) Expression in vein grafts derived from control or Ephrin-B2/Fc–treated mice, of phos-
phorylated Cav-1 (red), both (merge) phosphorylated Cav-1 (red) and total Cav-1 (green), and both (merge) phosphorylated Cav-1 (red) and Eph-B4 
(green). Counterstain is with DAPI (blue signal). n = 3. Bar, 50 µm. Arrowheads denote intimal-medial thickness. *, lumen.570 Eph-B4 prevents venous remodeling | Muto et al.
with EC-specific Cav-1 transgenic reconstitution, had 
greatly reduced thickness compared with vein grafts 
derived  from  Cav-1  KO  mice  and  almost  similar 
thickening to WT vein grafts (Fig. 9 A, right), suggest-
ing that the thickening response is a result of endothe-
lial Cav-1 and not global Cav-1 dysfunction.
Because Cav-1 limits vein graft thickening in a 
manner similar to that seen with Eph-B4 stimula-
tion, we next determined whether Cav-1 may be a 
mechanism of Eph-B4–mediated vein graft adapta-
tion. Control vein grafts implanted into littermate 
WT mice showed vein graft thickening that was 
suppressed by Ephrin-B2/Fc injection, as previously 
shown in Fig. 3 (Fig. 9, B [WT, red box], C [left, 
Ephrin-B2/Fc], and D [WT, red bar]). However, the 
thickened vein grafts in Cav-1 KO mice were un-
responsive to Ephrin-B2/Fc injection (Fig. 9, B [KO, 
red circle], C [right, Ephrin-B2/Fc], and D [KO, red bar]), 
with similar wall thickness as the control vein grafts. There 
were no significant differences in CD3+ infiltrating cells in 
any of the vein grafts, suggesting that the thickened Cav-1 
KO–derived vein grafts were not a result of T cell–mediated 
responses (Fig. 9 E). These results suggest that Cav-1 is 
downstream of Eph-B4 signaling during venous adapta-
tion, and that Cav-1 is an effector of Eph-B4–mediated vein 
graft adaptation.
In WT EC, Ephrin-B2/Fc stimulation of Eph-B4 leads to 
receptor tyrosine phosphorylation, which then directly or in-
directly interacts with Cav-1 (Fig. S4 A); however, Eph-B4 
within EC derived from Cav-1 KO mice retained the ability 
to phosphorylate tyrosine even though Cav-1 was not detect-
able (Fig. S4 A). In addition, EC derived from Cav-1 KO 
mice did not exhibit Ephrin-B2/Fc–dependent ERK de-
phosphorylation, as did WT EC (Fig. S4 B), which is consis-
tent with thicker vein grafts in veins derived from Cav-1 KO 
mice (Fig. 9). These results suggest that the unresponsiveness 
of Cav-1 KO vein grafts to Ephrin-B2/Fc treatment in vivo 
(Fig. 9, B [KO, red circle], C [right, Ephrin-B2/Fc], and D 
these  results  show  that  phosphorylation  of  Cav-1  in  vein 
grafts is correlated with Eph-B4 phosphorylation status and 
inversely correlated with vein graft thickness.
Cav-1 limits vein graft thickness and is a determinant  
of Eph-B4–mediated venous adaptation
To determine if Cav-1 is required for Eph-B4 suppression of 
vein graft wall thickening, we examined vein graft adaptation 
in WT and Cav-1 KO mice. Control vein grafts implanted 
into littermate WT mice showed similar vein graft thickening 
as that previously shown in Fig. 4 (Fig. 9 A, left). However, 
vein grafts derived from Cav-1 KO mice, implanted into WT 
hosts, showed significantly increased wall thickness (Fig. 9 A, 
middle), which was similar to that seen in vein grafts with re-
duced Eph-B4 function (Fig. 4). The increased wall thickness 
in vein grafts derived from Cav-1 KO mice, similar to the in-
creased thickness of vein grafts derived from Eph-B4+/ mice, 
confirms our previous data that Cav-1 phosphorylation is 
correlated with Eph-B4 phosphorylation (Fig. 8) and also 
shows that Cav-1 limits vein graft thickness. In addition, vein 
grafts derived from Cav-1 RC mice, e.g., Cav-1 KO mice 
Figure 9.  Ephrin-B2/Fc inhibition of vein wall thicken-
ing depends on Cav-1. (A) Vein grafts derived from WT, ho-
mozygous Cav-1 KO mice, or Cav-1 EC-reconstituted (Cav-1 
RC) mice were implanted into littermate mice, examined after 
4 wk, and stained with H&E. Arrows show vein graft wall.  
n = 2–7. Bar, 50 µm. (B) Vein graft wall thickness as deter-
mined by serial ultrasounds in mice. Vein grafts were derived 
from WT (squares) or Cav-1 KO mice (circles) and treated with 
control CD6/Fc (black) or Ephrin-B2/Fc (red). n = 5–7. Error 
bars denote SEM. (C) Vein grafts were derived from WT or  
Cav-1 KO mice, implanted into littermate WT mice, treated 
with control CD6/Fc or Ephrin-B2/Fc, examined after 4 wk, and 
stained with H&E. Arrows show vein graft wall. n = 5–7. Bar, 
50 µm. (D) Vein graft wall thickness in WT and Cav-1 KO vein 
grafts, with control CD6/Fc or Ephrin-B2/Fc treatment.  
n = 5–7. Error bars denote SEM. (E) Numbers of CD3 immuno-
reactive cells infiltrated into veins and vein grafts. Error bars 
denote SEM. n = 5–7. **, P < 0.01. n.s., not significant.JEM VOL. 208, March 14, 2011 
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being down-regulated suggests a novel feed-forward type of 
positive regulation associated with Eph-B4 and/or the venous 
environment. In addition, if venous adaptation to the arterial 
environment, that is, Eph-B4–dependent venous remodeling, 
is different from the response of the arterial wall to injury, then 
we might expect that strategies that inhibit arterial SMC prolif-
eration and/or migration, and neointimal hyperplasia, are not 
effective in preventing vein graft failure, as has been reported 
in clinical trials (Alexander et al., 2005; Conte et al., 2006).
We also show that the activated Eph-B4 receptor is asso-
ciated with Cav-1. Eph-B1 has previously been demonstrated 
to associate with Cav-1 (Vihanto et al., 2006), although it is 
not known whether compartmentalization to caveolae is a 
general feature of Eph receptor signaling or whether nonca-
veolae pools participate in cell function. However, our find-
ings that elimination of Cav-1 abolishes vein graft thinning   
in response to Ephrin-B2/Fc (Fig. 9) suggest that Cav-1 is a 
critical mediator of Eph-B4 function during vein graft adap-
tation. Although we have previously demonstrated that the 
role of Cav-1 as a mechanosensor of physical forces lies in 
EC and, therefore, it is unlikely that the lack of response to 
Ephrin-B2/Fc reflects global caveolin dysfunction (Yu et al., 
2006), the absence of Cav-1 in all cell types, and its pleotropic 
effects, do not exclude Cav-1 function in the vein graft smooth 
muscle cells.
RTKs  have  a  highly  conserved  consensus  sequence, 
XXXXX, where X is any amino acid and  is one of 
the aromatic acids Trp, Phe, or Tyr, which in the mouse Eph-
B4 receptor is located at amino acids 804–811, near the end 
of the intracellular tyrosine kinase domain (amino acids 610–
878) and close to the SAM domain (amino acids 911–960; 
Vihanto et al., 2006). Previous studies described this sequence 
as a putative site of interaction between Cav-1 and the RTK 
(García-Cardeña et al., 1997; Nystrom et al., 1999; Abulrob 
et al., 2004; Vihanto et al., 2006), although it is not known 
whether mutations of the site disrupt receptor function by 
prevention  of  protein–protein  interactions,  receptor  phos-
phorylation,  or  perhaps  other  mechanisms  such  as  subtle 
changes in quaternary structure (Bucci et al., 2000). Our mu-
tated Eph-B4 plasmids and adenovirus do not undergo tyro-
sine phosphorylation in response to Ephrin-B2/Fc (Fig. 5,   
D and F; and Fig. 6 A), suggesting that both tyrosine phosphory-
lation and/or interaction with Cav-1 are critical aspects of 
Eph-B4 signaling and function during vein graft adaptation 
(Fig. S5). This conserved motif has previously been shown to 
be necessary for the catalytic function of the kinase domain 
and other posttranslational processing, even in the absence of 
direct binding of the RTK to the Cav-1 scaffolding domain 
(Nystrom et al., 1999). It has also been previously reported 
that this motif may be a place of potential interaction with 
Cav-1, in addition to a site of potential compartmentalization 
of various signaling molecules allowing rapid and selective 
modulation of signal transduction (Cohen et al., 2004). How-
ever, in in vitro binding studies, we could not show direct 
binding between Eph-B4 and Cav-1 (unpublished data), sug-
gesting that Eph-B4 and Cav-1 interact indirectly.
[KO, red bar]) is specific to the interaction of Eph-B4 with 
Cav-1 during vein graft adaptation and not a result of the lack 
of Eph-B4 tyrosine phosphorylation (Fig. S5). These results 
also suggest that Cav-1 is a mechanism of Eph-B4 function 
during vein graft adaptation. Collectively, our results show 
that Eph-B4 phosphorylation and downstream signaling is 
active in adult venous EC and limits vein graft wall thickness 
during adaptation to the arterial environment, and that Cav-1 
is an important component for this Eph-B4 function.
DISCUSSION
Using a mouse model that recapitulates aspects of human vein 
graft adaptation, we show that stimulation of Eph-B4 signal-
ing is associated with vein grafts that remain morphologically 
thin and retain Eph-B4 protein, i.e., retain venous identity. 
These findings suggest that Eph-B4 remains active in normal 
adult veins and may promote conservation of normal venous 
architecture in adult tissues. Loss of Eph-B4 during venous 
transposition to the arterial circulation is directly responsible 
for loss of normal venous structure with excessive venous wall 
thickening and remodeling. Prevention of venous remodeling 
of adult vein grafts with either Ephrin-B2/Fc or adenovirus 
encoding WT Eph-B4 is consistent with our hypothesis that 
stimulation of Eph-B4 actively limits venous wall thickening. 
This new data suggests a function for Eph-B4 in adult veins 
where no such function has previously been reported. How-
ever, our findings that vein graft Eph-B4 function may be a 
result of endothelial Eph-B4 (Fig. 1 F and Fig. 3 B) and en-
dothelial Cav-1 (Fig. 8 E) do not exclude the possibility that 
Eph-B4 function may also be present and functional in vein 
graft smooth muscle cells. Indeed, Eph-B4 has been reported 
to be present in venous smooth muscle cells (Kudo et al., 
2007) and we demonstrate localization of phosphotyrosine to 
the media of veins treated with Ephrin-B2/Fc (Fig. 3 B). Addi-
tionally, Eph-B4 may be retained in some of the smooth muscle 
cells in vein grafts implanted into Ephrin-B2/Fc–treated mice 
(Fig. 3 H), and we show only partial recovery of thin walls in 
vein  grafts  derived  from  Cav-1-RC  mice,  i.e.,  mice  with 
Cav-1 reconstituted only in the EC (Fig. 9 A). All of these 
data suggest that Eph-B4 signaling in vein graft smooth mus-
cle cells may be part of the mechanism by which Eph-B4 
limits venous adaptation to the arterial environment.
Veins do not form as a default pathway in response to lack 
of arterial expression cues. Rather, COUP-TFII expression 
actively determines venous identity during embryogenesis 
(You et al., 2005). Regardless of the upstream regulatory con-
trol mechanisms of Eph-B4 expression during embryogenesis, 
our findings that Eph-B4 regulates venous wall thickening in 
the adult shows that Eph-B4 is not simply a passive marker of 
venous tissue but that Eph-B4 remains functional in adult 
veins. As such, although the function of Eph-B4 in adult veins 
is not currently known, it is not surprising that regulation of 
venous remodeling involves Eph-B4, an RTK confined to 
venous tissue, and therefore may be distinct from control of 
arterial remodeling. Our finding that Eph-B4 expression is 
preserved with Ephrin-B2/Fc treatment (Fig. 3) rather than 572 Eph-B4 prevents venous remodeling | Muto et al.
Biosciences), and human IgG Fc–FITC conjugated (Sigma-Aldrich). Sec-
ondary antibodies were: biotin-conjugated anti–goat IgG and anti–mouse 
IgG, HRP-conjugated anti–goat IgG (Santa Cruz Biotechnology, Inc.), 
biotin-conjugated anti–rat IgG (Vector Laboratories), HRP-conjugated 
anti–rabbit  IgG  and  anti–mouse  IgG  (Cell  Signaling Technology), Alexa 
Fluor 488–, 568–, and 680–conjugated IgG (Invitrogen), and IRDye 800–
conjugated IgG (Rockland). SlowFade Gold antifade reagent with DAPI   
(Invitrogen) was used for nuclear staining for immunofluorescence. Protein-
ase K (Roche), NovaRED Substrate kit, RTU horseradish peroxidase 
streptavidin, and DAB Substrate kits (Vector Laboratories) were used for 
immunohistochemistry.  Recombinant  mouse  Ephrin-B2/Fc  chimera  and 
CD6/Fc chimera (R&D Systems) were used for stimulating the Eph-B4 
receptor and the negative control, respectively.
Mouse vein graft model. All procedures, protocols, and medications were 
approved by the Institutional Animal Care and Use Committee and were 
performed and administered within National Institutes of Health and ethical 
guidelines. 12-wk-old C57BL/6 WT (Harlan) and EphB4+/ mice (The 
Jackson Laboratory) were purchased, and Cav-1/ and Cav-1 RC mice 
were generated as previously described (Yu et al., 2006; Murata et al., 2007). 
To avoid both background effects—i.e., confounding strain-based differences 
in susceptibility to vein wall thickening—and potential immunological re-
actions from transplantation across strains, all procedures used mice that were 
derived from the same background as a reference group. In particular, EphB4+/ 
mice were B6.129S7 background and bred to C57BL/6 mice for two addi-
tional generations so that littermate mice were used for reference groups. 
Cav-1/ and Cav-1 RC mice and their littermates were bred in a similar 
fashion, as previously described (Yu et al., 2006; Murata et al., 2007).
To obtain veins, an 2.0-mm segment of the intrathoracic inferior vena 
cava was isolated and excised. To implant the vein graft, a midline incision was 
made in the abdomen of a recipient mouse and the infrarenal abdominal 
aorta was exposed. The abdominal aorta was temporarily occluded with 
atraumatic micro-clamps and a segment corresponding to the length of the 
vein graft was excised. The vein was sutured into the arterial circulation using 
10–0 nylon in continuous fashion.
Vein grafts were followed postoperatively using the Vevo770 High-
Resolution Imaging System (VisualSonics). At fixed time points after surgery, 
mice were sacrificed to allow explantation of the vein graft. Tissue was either 
frozen with RNA stabilization reagent (QIAGEN) or was explanted for par-
affin embedding after circulatory flushing with ice-cold PBS followed by 4% 
paraformaldehyde perfusion-fixation.
Vein graft wall thickness, lumen diameter, and outer wall diameter (elas-
tic lamina) was measured in elastin-stained sections using computer mor-
phometry (ImageJ; National Institutes of Health). The wall expansion ratio 
was computed by measuring the mean inner wall diameter at four points,   
using ultrasound, during systole and compared with that measured during 
diastole. The wall compliance ratio was computed by measuring, using ultra-
sound, the relative compliance during systole and compared with that mea-
sured during diastole.
Measurement of cell proliferation and apoptosis in vein graft sections 
was made by performing immunohistochemistry, using the antibodies di-
rected against phospho-histone H3, and cleaved caspase 3, respectively. The 
percentage of positive cells was directly counted in at least five sections, using 
sections that contained at least 100 cells per field.
Ephrin-B2/Fc treatment in vivo. Both host and donor mice were treated 
with 20 µg of either Ephrin-B2/Fc or CD6/Fc (R&D Systems; intraperito-
neal; Noren et al., 2006) starting 24 h before surgery, with additional doses 
given every 48 h, starting on the day after surgery, until the day before 
harvest. No clustering of Ephrin-B2/Fc was performed.
Construction of WT Eph-B4 and mutants of the Eph-B4 kinase   
domain. The cDNA sequence of mouse Eph-B4 was purchased from Open 
Biosystems. The Eph-B4 construct sequence was amplified by PCR with 
Platinum Pfx DNA polymerase (Invitrogen) using the following primers: 
Our data also shows that stimulation of Eph-B4 signaling 
also stimulates Cav-1 phosphorylation, both in vitro (Fig. 8,   
A and B) and in vivo during vein graft adaptation (Fig. 8, D–F). 
Although the functional significance of Cav-1 phosphoryla-
tion is not currently clearly understood, these data show that 
Eph-B4 and Cav-1 are linked. Because Cav-1 regulates eNOS 
(Fig. 7 F; Gratton et al., 2000, 2004) and NO is a regulator of 
vein graft wall thickness (Kibbe et al., 2001; Mayr et al., 2006), 
it is possible that Cav-1 mediates the effects of Eph-B4 func-
tion on vein graft wall thickness via modulation of eNOS 
function. The phenotype of Cav-1 KO vein grafts (Fig. 9, B–D) 
shows failure to remodel, which is similar to the failure of 
vessel  remodeling  in  eNOS  KO  mice  that  we  previously 
demonstrated (Rudic et al., 1998). These data suggest that 
both Cav-1 and eNOS are downstream mediators of Eph-B4–
dependent vein graft remodeling.
We use a mouse model of venous transposition to the 
arterial environment that recapitulates aspects of human vein 
graft adaptation. In particular, certain aspects are important 
features of this model. The use of the inferior vena cava as a 
conduit allows remodeling of the vein graft to a diameter 
similar to that of the artery (Fig. S1, D and G). This remodel-
ing, or change in both vessel diameter and wall thickness, is 
similar to the remodeling that occurs in successful human 
vein grafts after implantation (Owens et al., 2006, 2008).   
In addition, the hand-sewn anastomosis allows flexible re-
modeling of the anastomotic area in accordance with the 
main body of the vein graft, unlike the cuff anastomotic tech-
nique that is fixed and prevents remodeling. This compliance 
of the anastomoses allows laminar-like flow through the body 
of the graft with only small amounts of turbulence at the 
anastomoses (ultrasound data not depicted) rather than the 
large amounts of turbulence that are expected with the cuff 
technique. Lastly, the use of WT C57BL/6 mice, rather than 
hypercholesterolemic mice, allows us to model normal vein 
graft adaptation as a first understanding of vein graft responses 
to transplantation to the arterial environment.
In conclusion, we show that Eph-B4 is not simply a pas-
sive marker of adult veins. Rather, stimulation of Eph-B4 
during vein graft adaptation promotes retention of venous 
identity and prevents vein wall thickening. As such, it is possi-
ble that vein graft failure may be prevented by promotion and 
continual stimulation of venous identity. Because Eph-B4 is a 
determinant of venous identity during embryogenesis, stimu-
lation of Eph-B4 in adult cells represents a new paradigm to 
treat adult diseases. We believe that the success of this strategy 
may depend on reactivation of this differentiation program in 
the environmental context of loss of venous identity.
MATERIALS AND METHODS
Antibodies and reagents. Primary antibodies to the following antigens 
were obtained as follows: mouse Eph-B4 (R&D Systems), human Eph-B4, 
C4d (Lifespan), Ephrin-B2 (Neuromics), phosphotyrosine (Millipore), Cav-1, 
Cav-2 (BD), Cav-1, HA-tag (Santa Cruz Biotechnology, Inc.), human 
smooth muscle actin–HRP conjugated (Dako), F4/80 (AbD Serotec), 
GAPDH, Myc-Tag, phospho-histone H3, cleaved caspase-3, HA-tag (Cell 
Signaling Technology), RasGAP (Novus Biologicals), Ephexin-1 (ECM   JEM VOL. 208, March 14, 2011 
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human patients undergoing cardiac transplantation, or from patients with pe-
ripheral bypass undergoing amputation for distal ischemia without infection 
or a thrombosed vein graft. Specimens from cardiac patients were a gift from 
G. Tellides (Yale University School of Medicine, New Haven, CT). Vein 
grafts were fixed in 10% formalin. Approval of the institutional Human Inves-
tigation Committee was obtained.
Specimens were embedded in paraffin and cut in 5-µm cross section. 
Hematoxylin & eosin (H&E), Masson trichrome, and van Gieson elastin 
staining were performed for all samples. All sections were treated for antigen 
retrieval using either 10 mmol/liter citrate buffer, pH 6.0 (with boiling) or 
20 µg/ml proteinase K (room temperature) for 10–15 min. Cultured cells 
were cultured on gelatin-coated coverslips and fixed with iced methanol. No 
clustering treatments were performed.
Primary antibody treatment was performed according to the manufac-
turer’s instructions and optimized concentrations where needed. For immuno-
histochemistry, secondary detection was performed using DAB as well   
as NovaRED substrate (Vector Laboratories). Sections were counterstained 
with Mayer’s Hematoxylin. For immunofluorescence, secondary detection 
was performed using Alexa Fluor 488 and 568 and counterstained with 
DAPI. Images were captured with an AxioImager A1 (Carl Zeiss, Inc.) under 
identical conditions.
Immunoprecipitation. Cells were scraped with RIPA buffer supplemented 
with Pefabloc SC PLUS and Complete Protease Inhibitor Cocktail (Roche). 
Protein concentration was measured using the protein assay reagent (Bio-Rad 
Laboratories), and 500 µg of protein was precleared with washed protein 
G agarose beads (Millipore). Samples were incubated with each antibody of in-
terest overnight at 4°C and then incubated with washed protein G agarose 
beads. No clustering treatments were performed. The beads were washed three 
times and resuspended in 50 µl Laemmli’s sample buffer for final denaturation.
Sucrose gradient separation. MLEC were washed twice with PBS and 
scraped into ice-cold 500 mM sodium carbonate, pH 11, supplemented with 
1 mg/ml protease inhibitor cocktail (Roche), dounce homogenized, and 
sonicated. The homogenate was then adjusted to 42.5% sucrose by the addi-
tion of 2 ml of 85% sucrose prepared in MBS (25 mM MES, pH 6.5, and 0.5 M 
NaCl) and placed at the bottom of an ultracentrifuge tube. A 5–30% discon-
tinuous sucrose gradient was formed (2 ml of 5% sucrose and 6 ml of 30% 
sucrose, both in MES containing 250 mM sodium carbonate) and centri-
fuged at 35,000 rpm for 18 h. 12 1-ml gradient fractions were collected from 
the top, mixed with SDS/PAGE loading buffer, and equal volumes were 
loaded, run on the SDS/12% PAGE, and Western blotted.
Western blotting. Equal amounts of protein from each experimental group 
were loaded for SDS-PAGE, followed by Western blot analysis. The mem-
branes were probed with antibodies as described in Antibodies and reagents, 
without any clustering treatments. Membrane signals were detected using the 
Odyssey infrared imaging system (LI-COR Biosciences) or the ECL detec-
tion reagent (GE Healthcare).
Cell migration. EC migration was performed using a modified Boyden 
chamber as previously described (Dardik et al., 2005). No clustering treat-
ments were used.
Flow  cytometry. WT and EphB4+/ EC were analyzed by indirect   
fluorescence-assisted flow cytometry. Cells were collected in cold PBS and 
immediately preserved with 0.5% paraformaldehyde. The cells were pre-
treated with Ephrin-B2/Fc to saturate surface Eph-B4 receptors, washed 
with cold PBS, and tagged with FITC-conjugated anti-Fc antibodies. Cells 
were analyzed in a flow cytometer (FACSCalibur; BD) in the FL-1 channel 
for FITC intensity (detected at 530 nm). Negative controls did not include 
the anti-Fc FITC antibody.
Statistical analysis. Results are presented as mean value ± SEM, and com-
pared with analysis of variance. Results were considered significant when   
P < 0.05 (StatView; SAS Institute).
forward, 5-AAACTAGTACCATGGAGCTCCGAGCGCTGCTG-3 and 
reverse, 5-CGATCGAGAACTGCTGGGCTGGTCCCCC-3. The PCR 
product was prepared for insertion into the pShuttle-IRES-hrGFP-2 plasmid 
vector by digestion with SpeI and PvuI.
For point mutation of the Eph-B4 kinase domain (amino acid residues 
804–811, sequence WSYGIVMW), the QuikChange Lightning Site-Directed 
Mutagenesis kit (Stratagene) was used with the following primers: w804a for-
ward, 5-CACCTCTGCCAGTGATGCCGCGAGCTATGGGATCGT-
CATG-3  and  reverse,  5-CATGACGATCCCATAGCTCGCGGCATC-
ACTGGCAGAGGTG-3;  w811f  forward,  5-GCTATGGGATCGTCAT-
GTTCGAGGTCATGTCTTTTGGG-3 and reverse, 5-CCCAAAAGA-
CATGACCTCGAACATGACGATCCCATAGC-3.  Colonies  showing  up-
take of the construct were screened with sequencing using the following primer: 
5-GAACTCCTCTGATCCCACCTACACAAGTTC-3.
Eph-B4 transduction of vein grafts in vivo. First generation replication-
defective adenoviruses expressing HA-tagged full-length mouse WT Eph-B4 
(Ad-Eph-B4-wt), or Eph-B4 containing the mutation w804a (Ad-Eph-B4-
w804a), were generated with the previously constructed plasmids using the 
AdEasy Adenoviral Vector System (Stratagene) and purified by cesium chlo-
ride centrifugation. The adenoviral titers were quantified by end-point dilu-
tion as previously described (Nicklin, 1999), and the MOI was calculated on 
the basis of the infective titer (pfu/ml).
After harvest from the donor mouse, the preimplantation vein was en-
tirely submerged in solution with adenovirus (1.0 × 109 pfu) for 20 min on 
ice. After adenoviral transduction, the graft was immediately implanted into 
the recipient mouse as described in Mouse vein graft model. After implanta-
tion, the remainder of the adenovirus solution was mixed with pluronic gel 
(final concentration 20%, final volume 20 µl) and applied to the vein graft 
adventitia, as previously described (Kudo et al., 2007).
Cell culture. Primary cultures of mouse lung ECs (MLECs) were isolated 
as previously described. These ECs behave similarly to ECs derived from pe-
ripheral veins (Ackah et al., 2005). Isolated MLECs were maintained with 
EBM-2/EGM-2 MV SingleQuot kit Supplement & Growth Factors (Lonza) 
containing 15% fetal bovine serum. Human embryo kidney (HEK) 293T 
cells and COS cells were cultured with high-glucose Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum.
NO release analysis. NO production by MLEC was analyzed as previously 
described (Fulton et al., 1999; Fernández-Hernando et al., 2006). In brief, 
conditioned medium was examined 0 and 24 h after Ephrin-B2/Fc treat-
ment, without any clustering treatments. The media was processed for the 
measurement of nitrite (NO2
) by an NO-specific chemiluminescence ana-
lyzer (Sievers).
RNA extraction and RT quantitative PCR. Total RNA was isolated 
from cells or tissue using TRIzol Reagent (Invitrogen) and RNA was cleaned 
using the RNeasy Mini kit with digested DNase I (QIAGEN). For quantifi-
cation of total RNA, each sample was measured using the RiboGreen RNA 
Assay kit (Invitrogen), and RNA quality was confirmed by the 260/280-nm 
ratio and random samples confirmed with 1.2% formaldehyde-agarose gel 
electrophoresis. RT was performed using the SuperScript III First-Strand 
Synthesis Supermix (Invitrogen) according to the manufacturer’s instruc-
tions. Real-time quantitative PCR was performed using SYBR Green Su-
permix (Bio-Rad Laboratories) and amplified for 40 cycles using the iQ5 
Real-Time PCR Detection system (Bio-Rad Laboratories). Correct target 
amplification and exclusion of nonspecific amplification was confirmed by 
2% agarose gel electrophoresis, and primer efficiencies were determined by 
melting curve analysis. All samples were normalized by GAPDH and/or 18s 
RNA amplification.
Immunohistochemistry and immunofluorescence. Mouse vein graft 
samples were fixed as described in Mouse vein graft model. Human vein and 
vein graft specimens were obtained as previously described (Kudo et al, 
2007). In brief, patent saphenous vein and vein grafts were explanted from 574 Eph-B4 prevents venous remodeling | Muto et al.
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